Intas Eyes Biosimilar Lucentis, Avastin To Boost Oncology Presence
This article was originally published in The Pink Sheet Daily
Executive Summary
Intas is bracing up for a sizable position in the Indian biosimilars market. Opportunities are large with growing patient numbers and scant supplies of affordable medicines, which are helping steer the company to growth rates upwards of 30%.
You may also be interested in...
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
Lee Takes India Compulsory License Fight To Saxagliptin
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.
Could Indian heart stent study findings lead to price cuts?
India’s top regulatory agencies are weighing up the findings from a study it had commissioned that looks at the clinical benefits of heart stents, with the possible aim of using the results to back the use of cheaper, locally-produced devices.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: